ISR

ISORAY
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6000
-0.0326
-5.15%
Opening 12:53 09/21 EDT
OPEN
0.6100
PREV CLOSE
0.6326
HIGH
0.6199
LOW
0.5900
VOLUME
386.75K
TURNOVER
--
52 WEEK HIGH
1.060
52 WEEK LOW
0.2875
MARKET CAP
41.34M
P/E (TTM)
-12.0240
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AngioDynamics launches Auryon Atherectomy System in U.S.
AngioDynamics (ANGO) has launched Auryon Atherectomy System, a newly-developed innovative laser technology for the treatment of Peripheral Artery Disease ((PAD)), including Critical Limb Ischemia ((CLI)) and In-Stent Restenosis (ISR) with
Seekingalpha · 4h ago
IsoRay, Inc. (NYSEMKT:ISR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's shaping up to be a tough period for IsoRay, Inc. (NYSEMKT:ISR), which a week ago released some disappointing...
Simply Wall St. · 2d ago
Mid-Afternoon Market Update: Dow Tumbles 300 Points; COMPASS Pathways Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 1.11% to 27591.20 while the NASDAQ fell 1.68% to 10,727.08. The S&P also fell, dropping 1.42% to 3,309.30.
Benzinga · 2d ago
Mid-Day Market Update: Nasdaq Turns Lower; Westport Fuel Systems Shares Surge
Midway through trading Friday, the Dow traded down 0.11% to 27872.20 while the NASDAQ fell 0.58% to 10,847.47. The S&P also fell, dropping 0.39% to 3,343.85.
Benzinga · 3d ago
5 Stocks To Watch For September 18, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 3d ago
IsoRay (ISR) Reports Q4 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -17.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
IsoRay EPS misses by $0.01, misses on revenue
IsoRay (ISR): FQ4 GAAP EPS of -$0.02 misses by $0.01.Revenue of $2.28M (+18.8% Y/Y) misses by $0.41M.Shares -2.2%.Press Release
Seekingalpha · 3d ago
Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
RICHLAND, Wash., Sept. 16, 2020 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer Fall
GlobeNewswire · 5d ago
More
No Data
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ISR stock price target is 1.500 with a high estimate of 1.750 and a low estimate of 1.250.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 3.97M
% Owned: 5.87%
Shares Outstanding: 68.90M
TypeInstitutionsShares
Increased
3
180.54K
New
3
75.96K
Decreased
3
935.88K
Sold Out
6
261.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.57%
Pharmaceuticals & Medical Research
-3.29%
Key Executives
Chairman/Independent Director
Michael McCormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Executive Vice President/Director of Sales/Director of Marketing
Michael Krachon
Chief Accounting Officer/Controller
Mark Austin
Other
William Cavanagh
Secretary
Krista Cline
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ISR stock price target is 1.500 with a high estimate of 1.750 and a low estimate of 1.250.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ISR
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.